ATE289348T1 - Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon - Google Patents

Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon

Info

Publication number
ATE289348T1
ATE289348T1 AT96929066T AT96929066T ATE289348T1 AT E289348 T1 ATE289348 T1 AT E289348T1 AT 96929066 T AT96929066 T AT 96929066T AT 96929066 T AT96929066 T AT 96929066T AT E289348 T1 ATE289348 T1 AT E289348T1
Authority
AT
Austria
Prior art keywords
methods
cell culture
synthetase
cell cultures
vaccine production
Prior art date
Application number
AT96929066T
Other languages
English (en)
Inventor
Allan S Lau
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE289348T1 publication Critical patent/ATE289348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96929066T 1995-08-22 1996-08-22 Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon ATE289348T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US262195P 1995-08-22 1995-08-22
PCT/US1996/013745 WO1997008292A1 (en) 1995-08-22 1996-08-22 Methods for enhancing the production of viral vaccines in cell culture by interferon suppression

Publications (1)

Publication Number Publication Date
ATE289348T1 true ATE289348T1 (de) 2005-03-15

Family

ID=21701659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929066T ATE289348T1 (de) 1995-08-22 1996-08-22 Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon

Country Status (10)

Country Link
US (6) US5840565A (de)
EP (2) EP0846174A4 (de)
JP (2) JP4267693B2 (de)
CN (1) CN1161469C (de)
AT (1) ATE289348T1 (de)
AU (2) AU707130B2 (de)
BR (1) BR9610550A (de)
CA (2) CA2229163C (de)
DE (1) DE69634360T2 (de)
WO (2) WO1997008324A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855519B2 (en) * 1995-08-22 2005-02-15 The Regents Of The University Of California Methods for enhancing the production of interferon in cell culture
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en) 1997-11-03 2004-05-25 Mount Sinai School Of Medicine Immortalized, homozygous stat1-deficient mammalian cell lines and their uses
DK1085904T3 (da) 1998-06-12 2013-02-25 Sinai School Medicine Svækkede minusstreng-vira med ændret interferon-antagonist-aktivitet til anvendelse som vacciner og lægemidler
US6762038B1 (en) * 1998-09-09 2004-07-13 The Cleveland Clinic Foundation Mutant cell lines and methods for producing enhanced levels of recombinant proteins
CA2376487A1 (en) * 1999-06-15 2000-12-21 Allan S. Lau Methods for enhancing the production of cytokines in cell culture
EP1067179A1 (de) * 1999-07-09 2001-01-10 Pierre Fabre Medicament Verfahren zur Selektion von attenuierten Paramyxoviridae verwenbare als Impstoffen und Therapeutika
US20010031859A1 (en) * 1999-09-08 2001-10-18 Lau Allan S. High level cytokine production with enhanced cell viability
DE60035515T2 (de) * 1999-09-08 2008-04-17 GeneTrol Biotherapeutics, Inc., Oakland Hohe zytokinproduktion mit verbesserter zelllebensfähigkeit
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
AU2001278139A1 (en) * 2000-08-04 2002-02-18 Chiron Corporation Enhanced replication of hcv rna
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
JP2005500816A (ja) * 2000-12-19 2005-01-13 ジーントロール バイオセラピューティクス， インコーポレイテッド サイトカイン産生を増加するための増大したｐｋｒ発現を有する細胞
DE10104094C1 (de) * 2001-01-31 2002-07-25 Angelika Vallbracht-Flehmig Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung
WO2003035824A1 (en) * 2001-10-25 2003-05-01 Bar-Ilan University Interactive transparent individual cells biochip processor
IL154677A0 (en) 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
US20060240548A1 (en) * 2003-06-26 2006-10-26 Mordechai Deutsch Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US8597597B2 (en) 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20070219149A1 (en) * 2003-08-11 2007-09-20 The Research Foundation For Microbial Diseases Of Osaka University Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
NZ603105A (en) * 2003-10-23 2014-08-29 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, oasi
BRPI0415771A (pt) * 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
JP2007520546A (ja) * 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
ES2694123T3 (es) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
EP1763665A1 (de) * 2004-07-07 2007-03-21 Seng Enterprises Limited Verfahren und vorrichtung zur identifizierung eines vertiefungsbildes auf einem bild einer komponente mit vertiefungen
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
EP1781404A2 (de) * 2004-08-25 2007-05-09 Seng Enterprises Limited Verfahren und vorrichtung zur isolierung von zellen
US20060051369A1 (en) * 2004-08-27 2006-03-09 Taylor Deborah R ADAR1 antiviral pathway
US20080107683A1 (en) * 2004-11-30 2008-05-08 David Hone Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
ATE480324T1 (de) 2005-01-25 2010-09-15 Seng Entpr Ltd Mikrofluidische vorrichtung zur untersuchung zellen
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
US8288120B2 (en) 2005-11-03 2012-10-16 Seng Enterprises Ltd. Method for studying floating, living cells
US20070196333A1 (en) * 2006-02-23 2007-08-23 Fu-Yung Lin Composition comprising mixtures of IFN-alpha subtypes
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
WO2009081409A2 (en) 2007-12-26 2009-07-02 Seng Enterprises Ltd. Device for the study of living cells
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2133358A1 (de) * 2008-06-10 2009-12-16 Universitätsklinikum Freiburg Rifttalfiebervieren-ähnliche Partikel und ihre Verwendung zur Immunisierung und als Testsystem
CA2733356C (en) 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
WO2010077986A2 (en) 2008-12-16 2010-07-08 Baxter International Inc. Production of viral vaccine
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
CA2825403C (en) 2011-01-27 2023-02-21 Gamma Vaccines Pty Limited Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
JP2015526062A (ja) * 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
MX2015010017A (es) * 2013-02-05 2016-03-04 Univ Georgia Lineas celulares para la produccion de virus y metodos de uso.
EP3261664A1 (de) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalenter schweineinfluenzavirusimpfstoff
WO2017070167A1 (en) * 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
KR102651055B1 (ko) 2016-03-24 2024-03-26 삼성디스플레이 주식회사 광학 필름 및 디스플레이 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
JPS5754586A (en) * 1980-09-18 1982-04-01 Ajinomoto Co Inc Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
JPS58209993A (ja) * 1982-05-31 1983-12-07 Mochida Pharmaceut Co Ltd インタ−フエロンの産生方法
AU572783B2 (en) * 1982-06-21 1988-05-19 Wellcome Foundation Limited, The Improvements in or relating to the production of antiviral agents
US4485038A (en) * 1982-10-19 1984-11-27 Health Research (Roswell Park Division) Method for the production and purification of human leukocyte interferon
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4745053A (en) * 1983-07-08 1988-05-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo Process for producing human interferon and method for assaying the interferon productivity of blood
JPS6062997A (ja) * 1983-09-17 1985-04-11 Mochida Pharmaceut Co Ltd インタ−フエロンの生産方法
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
ES2110411T3 (es) * 1989-08-25 1998-02-16 Chiron Corp Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t.
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
JPH05260981A (ja) * 1992-03-02 1993-10-12 Massachusetts Inst Of Technol <Mit> ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture

Also Published As

Publication number Publication date
EP0846160A1 (de) 1998-06-10
EP0846160B1 (de) 2005-02-16
AU6860896A (en) 1997-03-19
US7132271B2 (en) 2006-11-07
JP3432519B2 (ja) 2003-08-04
US20010001290A1 (en) 2001-05-17
US6159712A (en) 2000-12-12
CA2229163C (en) 2011-04-05
WO1997008324A1 (en) 1997-03-06
CN1161469C (zh) 2004-08-11
US6686190B2 (en) 2004-02-03
EP0846174A4 (de) 2003-02-05
EP0846174A1 (de) 1998-06-10
JPH11514344A (ja) 1999-12-07
MX9801423A (es) 1998-05-31
DE69634360D1 (de) 2005-03-24
CA2229405A1 (en) 1997-03-06
BR9610550A (pt) 1999-07-06
JP4267693B2 (ja) 2009-05-27
JPH11511324A (ja) 1999-10-05
US20040157310A1 (en) 2004-08-12
AU707130B2 (en) 1999-07-01
AU6857696A (en) 1997-03-19
US6673591B2 (en) 2004-01-06
CA2229163A1 (en) 1997-03-06
DE69634360T2 (de) 2005-12-29
CA2229405C (en) 2004-03-02
US6489144B1 (en) 2002-12-03
EP0846160A4 (de) 2002-01-02
WO1997008292A1 (en) 1997-03-06
US5840565A (en) 1998-11-24
US20010001709A1 (en) 2001-05-24
CN1200148A (zh) 1998-11-25

Similar Documents

Publication Publication Date Title
ATE289348T1 (de) Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
ATE466932T1 (de) Vermehrung von viren in zellkultur
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
DK15182A (da) Fremgangsmaade til fremstilling af recombinant-dna
ES2156852T3 (es) Citoquina mamifera, il-11.
DE68929115D1 (de) Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
ATE370229T1 (de) Ein verstärkter, durch viren vermittelter dna- transfer
ATE27463T1 (de) Verfahren zur in vitro transformation von pflanzenprotoplasten mit plasmid-dns.
UA48936C2 (uk) Спосіб одержання вірусу курячої анемії (cav) у дволанцюговій формі, рекомбінантна нуклеїнова кислота (варіанти), діагностичний набір (варіанти), вакцинний препарат (варіанти), культура клітин (варіанти), спосіб одержання діагностичного набору (варіанти)
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
ATE530657T1 (de) Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
DK1693451T3 (da) Fremgangsmåde til dyrkning af myokardieceller
ATE366803T1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
Lelievre et al. Contact inhibition-plasma membranes enzymatic activities in cultured cell lines
WO2003027290A1 (fr) Procede pour conferer ou reguler la fertilite d&#39;un cytoplasme a sterilite male de riz bt au moyen d&#39;un gene de restauration de la fertilite, et procede d&#39;estimation de la presence d&#39;un gene de restauration de la fertilite
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
WO2001083754A3 (en) Cellular regulators of infectious agents and methods of use
ATE310823T1 (de) Expressionssystem zur produktion von proteinen in pilzen
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
ATE111527T1 (de) Herstellung und verwendung einer dna zur erhöhung der ausbeute bei der expression von rekombinanten genen.
BRPI0002694C1 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
ES2163405T3 (es) Virus recombinantes que comprenden sitios de escision proteoliticos artificiales.
SE7705701L (sv) Forfarande for utvinning av eggvita med forminskad nukleinsyrahalt ur mikroorganismer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0846160

Country of ref document: EP